Adlai Nortye (ANL) Competitors $1.58 +0.08 (+5.00%) As of 07/2/2025 02:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock ANL vs. SLRN, VOR, NBTX, BTMD, TVGN, CGC, PRQR, CRDF, EPRX, and TVRDShould you be buying Adlai Nortye stock or one of its competitors? The main competitors of Adlai Nortye include Acelyrin (SLRN), Vor Biopharma (VOR), Nanobiotix (NBTX), biote (BTMD), Semper Paratus Acquisition (TVGN), Canopy Growth (CGC), ProQR Therapeutics (PRQR), Cardiff Oncology (CRDF), Eupraxia Pharmaceuticals (EPRX), and Tvardi Therapeutics (TVRD). These companies are all part of the "pharmaceutical products" industry. Adlai Nortye vs. Its Competitors Acelyrin Vor Biopharma Nanobiotix biote Semper Paratus Acquisition Canopy Growth ProQR Therapeutics Cardiff Oncology Eupraxia Pharmaceuticals Tvardi Therapeutics Adlai Nortye (NASDAQ:ANL) and Acelyrin (NASDAQ:SLRN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations. Does the media refer more to ANL or SLRN? In the previous week, Adlai Nortye had 1 more articles in the media than Acelyrin. MarketBeat recorded 1 mentions for Adlai Nortye and 0 mentions for Acelyrin. Adlai Nortye's average media sentiment score of 0.93 beat Acelyrin's score of 0.00 indicating that Adlai Nortye is being referred to more favorably in the media. Company Overall Sentiment Adlai Nortye Positive Acelyrin Neutral Is ANL or SLRN more profitable? Adlai Nortye's return on equity of 0.00% beat Acelyrin's return on equity.Company Net Margins Return on Equity Return on Assets Adlai NortyeN/A N/A N/A Acelyrin N/A -44.12%-39.02% Which has preferable valuation and earnings, ANL or SLRN? Adlai Nortye has higher revenue and earnings than Acelyrin. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdlai Nortye$5M11.62-$51.87MN/AN/AAcelyrinN/AN/A-$381.64M-$2.69-0.84 Do analysts recommend ANL or SLRN? Adlai Nortye currently has a consensus target price of $9.00, indicating a potential upside of 471.43%. Acelyrin has a consensus target price of $9.60, indicating a potential upside of 322.91%. Given Adlai Nortye's higher possible upside, equities analysts clearly believe Adlai Nortye is more favorable than Acelyrin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adlai Nortye 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Acelyrin 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Do institutionals & insiders believe in ANL or SLRN? 35.2% of Adlai Nortye shares are owned by institutional investors. Comparatively, 87.3% of Acelyrin shares are owned by institutional investors. 13.6% of Acelyrin shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, ANL or SLRN? Adlai Nortye has a beta of -0.95, meaning that its share price is 195% less volatile than the S&P 500. Comparatively, Acelyrin has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. SummaryAdlai Nortye beats Acelyrin on 7 of the 12 factors compared between the two stocks. Get Adlai Nortye News Delivered to You Automatically Sign up to receive the latest news and ratings for ANL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANL vs. The Competition Export to ExcelMetricAdlai NortyeMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.35M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E RatioN/A21.3126.2319.90Price / Sales11.62278.47413.23113.66Price / CashN/A41.4736.1356.90Price / Book2.287.518.045.38Net Income-$51.87M-$55.05M$3.15B$248.50M7 Day Performance1.61%2.07%1.44%2.04%1 Month Performance-3.97%4.84%3.62%4.84%1 Year Performance-56.73%5.37%34.68%20.23% Adlai Nortye Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANLAdlai Nortye1.9614 of 5 stars$1.58+5.0%$9.00+471.4%-53.8%$55.35M$5M0.00127SLRNAcelyrinN/A$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135VORVor BiopharmaN/A$1.83+13.0%N/AN/A$228.68MN/A-1.21140News CoverageAnalyst UpgradeGap UpHigh Trading VolumeNBTXNanobiotix2.4603 of 5 stars$4.82+1.9%$8.00+65.9%-7.1%$227.21M$39.18M0.00100Gap DownBTMDbiote3.4091 of 5 stars$4.13+2.7%$8.00+93.7%-45.2%$225.95M$197.19M6.77194TVGNSemper Paratus Acquisition4.0218 of 5 stars$1.22-2.8%$10.00+723.0%+75.8%$223.43MN/A0.003CGCCanopy Growth2.6365 of 5 stars$1.21-1.2%$2.00+66.0%-81.0%$221.56M$225.65M-0.303,150PRQRProQR Therapeutics2.1302 of 5 stars$2.01-1.3%$8.00+297.2%+29.5%$212.00M$20.46M-5.76180News CoverageCRDFCardiff Oncology1.6866 of 5 stars$3.19+1.1%$9.88+210.0%+72.6%$211.90M$680K-3.4620EPRXEupraxia Pharmaceuticals2.1729 of 5 stars$5.89+2.3%$11.00+86.8%+117.1%$211.80MN/A-7.7529Analyst RevisionGap UpTVRDTvardi TherapeuticsN/A$22.61-3.1%$71.50+216.2%N/A$211.63M$7.14M0.0080 Related Companies and Tools Related Companies Acelyrin Alternatives Vor Biopharma Alternatives Nanobiotix Alternatives biote Alternatives Semper Paratus Acquisition Alternatives Canopy Growth Alternatives ProQR Therapeutics Alternatives Cardiff Oncology Alternatives Eupraxia Pharmaceuticals Alternatives Tvardi Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANL) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredMake 22x more from this summer’s Bitcoin boomBitcoin is on fire again. Wall Street’s piling in. ETFs are smashing volume records. And regular investors ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adlai Nortye Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Adlai Nortye With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.